Progesterone (Prometrium) and Ketamine Therapy | Tovani Health
Prometrium (Progesterone) — Progestin (HRT, fertility, sleep adjunct)
Verdict at Tovani Health
Compatible; mild sedation if taken at bedtime, no other concern.
Progesterone and ketamine have no clinically significant interaction. Micronized progesterone is mildly sedating when taken at bedtime, which is intentional; the sedation window does not typically overlap with morning sessions.
If you take Prometrium regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Prometrium interacts with ketamine
Progesterone binds progesterone receptors. Its metabolite allopregnanolone is a GABA-A positive allosteric modulator, which produces the mild sedation. The dose is too low to produce clinically meaningful stacking with ketamine.
What we do at intake
Continue as normal. Take at bedtime as typically prescribed.
Bottom line
Progesterone and ketamine have no clinically significant interaction. Micronized progesterone is mildly sedating when taken at bedtime, which is intentional; the sedation window does not typically overlap with morning sessions.
Frequently Asked Questions
Will Prometrium make me too sleepy for a ketamine session?
Not at the doses typically prescribed for HRT. If you have noticed strong daytime sedation, mention it during intake.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Prometrium (Progesterone) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Comprehensive clinical pharmacokinetics/pharmacodynamics review of ketamine including CYP-mediated drug interactions (CYP3A4, CYP2B6).
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.